AstraZeneca PLC

Board/Management Information • Oct 28, 2025

National Storage Mechanism | Additional information

RNS Number : 9938E

AstraZeneca PLC

28 October 2025

28 October 2025

Director Declaration

AstraZeneca PLC (the Company) today announced that Euan Ashley, Non-Executive Director of the Company, has been appointed a director of DexCom, Inc. with effect from 24 October 2025.

This announcement is made pursuant to Listing Rule 6.4.9 (2).

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit  astrazeneca.com  and follow the Company on Social Media  @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click  here . For Media contacts, click  here .

Matthew Bowden

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNQDLFLEBLZFBZ